Highlights

The vaccine will be affordable & accessible
Cervical cancer in India ranks as the second-most frequent cancer among women
Phase three results showed a robust immune response in 100% of the vaccine recipients

Latest news

Shokz OpenRun Pro 2 Review: Great Sound Without Shutting Out The World

Jabra Evolve3 85 Review: A ₹75,000 Headset Built For The Noisy Workday

Apple Redefines the Pro Laptop: New MacBook Pro Debuts OLED PROLED XDR Display, Touch Support, and M5 Pro

Oppo Enco X4 Review: Dynaudio Sound, Adaptive ANC, And 52-Hour Battery Life

Apple Reboots Creator Studio Suite with MotionVFX, AI Assistants, and Cross-App Workflows

Apple Updates Its iMac With M6 Chip, Seven Vibrant Colours and Advanced AI Features

Apple Unveils New 14-Inch MacBook Pro With M6 Chip, Promising 24-Hour Battery Life and Big AI Gains

HP OmniPad 12 Review: HP’s first Android tablet gets the basics right, but not without its issues

Good news! India to launch cervical cancer vaccine by year-end

Name: Good news! India to launch cervical cancer vaccine by year-end
Uploaded: 2022-07-20T11:12:44.000+05:30
Duration: T00M58S
Channel: Editorji News Desk
Description: Cancer Vaccine: The Serum Institute of India (SII) is all set to launch its indigenously-developed cervical cancer vaccine by the end of this year.

Cervical Cancer Vaccine : The Serum Institute of India (SII) is all set to launch its indigenously-developed cervical cancer vaccine by the end of this year.

Updated: Sep 02, 2022 10:53

Editorji News Desk

Join our WhatsApp Channel

Good news! India to launch cervical cancer vaccine by year-end

Cancer Vaccine: After the Drugs Controller General of India's (DCGI) approval, the Serum Institute of India (SII) is all set to launch its indigenously-developed cervical cancer vaccine later this year.

According to SII, the Quadrivalent Human Papillomavirus vaccine (qHPV) to treat cervical cancer in women will be affordable and accessible.

Cervical cancer in India ranks as the second-most frequent cancer among women between 15 and 44 years of age. The vaccine is based on VLP (virus-like particles), similar to the Hepatitis B vaccine and protects by generating antibodies against the HPV virus L1 protein.

The trials for the vaccine started in 2019 and thousands of participants in the age group of 9‐26 years were part of the trials across India. Phase three results showed a robust immune response in 100 per cent of the vaccine recipients with good safety records.

Also watch: Researchers develop a new single-shot vaccine to cure AIDS